Supplier
ROCHE
Monza · ITA
Track this recordWith Adjudera Pro, get alerted before a contract here runs out.
Awards
16
Total awarded
€30.0m
16 / 16 with a value
Buyers
1
Sectors
1
Reg. 00747170157
Contracts this supplier holds that are running out
- €5,924,864
21 Nov 2026
estimated - €31,271
21 Nov 2026
estimated - €2,685,825
21 Nov 2026
estimated - €50,673
21 Nov 2026
estimated - €575,001
21 Nov 2026
estimated - €804,056
21 Nov 2026
estimated - €9,303,717
21 Nov 2026
estimated - €2,209,043
21 Nov 2026
estimated - €2,486,175
21 Nov 2026
estimated - €459,815
21 Nov 2026
estimated - €149,190
21 Nov 2026
estimated - €1,821,448
21 Nov 2026
estimated - €2,921
21 Nov 2026
estimated - €2,242,069
8 May 2027
estimated
Awards
| Awarded | Buyer | Winner | Contract value | Published |
|---|---|---|---|---|
| POLATUZUMAB VEDOTIN | PuntoZero S.c.ar.l. | ROCHE | €2,242,069 | 7 May 2026 |
| LEVODOPA/BENSERAZIDE | PuntoZero S.c.ar.l. | ROCHE | €2,921 | 20 Nov 2025 |
| RISDIPLAM | PuntoZero S.c.ar.l. | ROCHE | €1,821,448 | 20 Nov 2025 |
| PIRFENIDONE | PuntoZero S.c.ar.l. | ROCHE | €149,190 | 20 Nov 2025 |
| VISMODEGIB | PuntoZero S.c.ar.l. | ROCHE | €459,815 | 20 Nov 2025 |
| PERTUZUMAB + TRASTUZUMAB | PuntoZero S.c.ar.l. | ROCHE | €2,486,175 | 20 Nov 2025 |
| GLOFITAMAB | PuntoZero S.c.ar.l. | ROCHE | €2,209,043 | 20 Nov 2025 |
| PERTUZUMAB | PuntoZero S.c.ar.l. | ROCHE | €9,303,717 | 20 Nov 2025 |
| OBINUTUZUMAB | PuntoZero S.c.ar.l. | ROCHE | €804,056 | 20 Nov 2025 |
| ENTRECTINIB | PuntoZero S.c.ar.l. | ROCHE | €575,001 | 20 Nov 2025 |
| COBIMETINIB EMIFUMARATO | PuntoZero S.c.ar.l. | ROCHE | €50,673 | 20 Nov 2025 |
| ALECTINIB | PuntoZero S.c.ar.l. | ROCHE | €2,685,825 | 20 Nov 2025 |
| OSELTAMIVIR FOSFATO | PuntoZero S.c.ar.l. | ROCHE | €31,271 | 20 Nov 2025 |
| EMICIZUMAB | PuntoZero S.c.ar.l. | ROCHE | €5,924,864 | 20 Nov 2025 |
| FARICIMAB | PuntoZero S.c.ar.l. | ROCHE | €384,593 | 17 Jun 2025 |
| MOSUNETUZUMAB | PuntoZero S.c.ar.l. | ROCHE | €823,670 | 17 Jun 2025 |